Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson maintains an Outperform rating on Revolution Medicines (NASDAQ:RVMD) and raises the price target from $45 to $55.
July 16, 2024 | 12:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Jay Olson maintains an Outperform rating on Revolution Medicines and raises the price target from $45 to $55.
The raised price target and maintained Outperform rating from a reputable analyst at Oppenheimer is likely to positively influence investor sentiment and drive short-term price appreciation for RVMD.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100